行情

XLRN

XLRN

Acceleron制药
NASDAQ

实时行情|Nasdaq Last Sale

94.85
+0.41
+0.43%
盘后: 94.85 0 0.00% 16:06 02/20 EST
开盘
94.14
昨收
94.44
最高
95.21
最低
92.37
成交量
26.41万
成交额
--
52周最高
95.95
52周最低
37.01
市值
50.35亿
市盈率(TTM)
-35.2262
分时
5日
1月
3月
1年
5年

分析师评级

11位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

XLRN 新闻

  • Acceleron Pharma (XLRN) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
  • Zacks.6小时前
  • Blood disorder startup files for $86M IPO
  • American City Business Journals.1天前
  • Is Acceleron Pharma Inc.'s (NASDAQ:XLRN) CEO Pay Justified?
  • Simply Wall St..2天前
  • H.C. Wainwright Maintains Buy on Acceleron Pharma, Raises Price Target to $129
  • Benzinga.2天前

更多

所属板块

生物技术和医学研究
+0.09%
制药与医学研究
-0.40%

热门股票

名称
价格
涨跌幅

XLRN 简况

Acceleron Pharma Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its research focuses on key natural regulators of cellular growth and repair, particularly the Transforming Growth Factor-Beta (TGF-beta), protein superfamily. It has four internally discovered therapeutic candidates that are in clinical trials, which include luspatercept, sotatercept, dalantercept and ACE-083. It offers a platform technology, IntelliTrap. It is also evaluating ACE-1332, a selective TGF-beta antagonist, for treatment of disorders with a fibrotic component, and additional molecules from its IntelliTrap platform for undisclosed therapeutic areas. Dalantercept is designed to treat cancers by inhibiting blood vessel formation by inhibiting signaling through the ALK1 receptor. ACE-083 is designed to promote muscle growth and function in specific, targeted muscles.
展开

Webull提供Acceleron Pharma Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。